Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Baricitinib in Refractory Non-infectious Non-anterior Uveitis
NCT05651880Phase 3Not yet recruiting
- Sponsor
- Rouen University Hospital
- Start
- Jul 2026
- Primary completion
- Dec 2029
- Modality
- Recombinant Proteins and Enzymes, Small Molecules, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of baricitinib in noninfectious uveitis (NIU), sponsored by Rouen University Hospital. Primary endpoint: Number of patients with complete remission at 6 months. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
baricitinib
03
Conditions
noninfectious uveitis (NIU)
Beyond the preview
Go deeper on NCT05651880.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05651880.